Loading company details...
Latest Form 4 (Nov 12, 2026): Robert Lorne Abel (EVP, Chief Scientific Officer, Platform): Exercise/Conversion of 21,927 shares, $372.8K.
Every alert includes an AI-written analysis of the filing, plus news and market context.
| Filed | Insider | Transaction | Shares | Value |
|---|---|---|---|---|
| Nov 12, 2026 | Robert Lorne Abel, EVP, Chief Scientific Officer, Platform | Exercise/Conversion | 21,927 | $372.8K |
| Nov 12, 2026 | Paul Jonathan Davie, EVP, Chief Commercial Officer, Global Head of Software Sales & Marketing | Grant/Award | 18,400 | n/a |
| Nov 10, 2026 | Yvonne Tran, EVP, CLO & CPO | Exercise/Conversion | 32,000 | $544.0K |
| Sep 21, 2026 | Karen Akinsanya, President, Head of Therapeutics R&D and Chief Strategy Officer, Partnerships | Exercise/Conversion | 31,599 | $137.1K |
| Jul 17, 2026 | Rachit Jain, EVP & CFO | Sale | 875 | $13.6K |
| Jun 29, 2026 | Richard Friesner | Gift | 679,373 | n/a |
| Jun 23, 2026 | Arun Oberoi | Grant/Award | 8,141 | n/a |
| Jun 23, 2026 | Jeffrey Chodakewitz | Grant/Award | 8,141 | n/a |
| Jun 23, 2026 | Richard Friesner | Grant/Award | 8,141 | n/a |
| Jun 23, 2026 | Gary L. Ginsberg | Grant/Award | 8,141 | n/a |